For example, bintrafusp alfa is currently being tested as a first‐line treatment for patients with advanced non‐small cell LC (NSCLC, which includes LUSC) with high PD‐L1 expression [38]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.